Chief Executive Robert Meadowcroft of the Muscular Dystrophy Campaign has kindly spoken to us about the UK’s Early Access to Medicines Scheme, enabling patients with rare diseases access to ‘groundbreaking’ treatments earlier.
This report discusses:
- Whether or not the UK’s Early Access to Medicines Scheme is a positive development
- What the government should be doing to enable those with rare diseases earlier access to medicines
- The Muscular Dystrophy Campaign – An extra op-ed piece written by Robert
To learn more about the topics above download a copy today!
Robert will be participating at the upcoming Fast Tracking Orphan Drugs Briefing on 10th July in London. Join us at the event to further hear his views on orphan drugs.